Приказ основних података о документу
Carborane Analogues of Fenoprofen Exhibit Improved Antitumor Activity
dc.creator | Useini, Liridona | |
dc.creator | Mojić, Marija | |
dc.creator | Laube, Markus | |
dc.creator | Lönnecke, Peter | |
dc.creator | Mijatović, Sanja | |
dc.creator | Maksimović-Ivanić, Danijela | |
dc.creator | Pietzsch, Jens | |
dc.creator | Hey‐Hawkins, Evamarie | |
dc.date.accessioned | 2023-02-03T08:26:41Z | |
dc.date.available | 2023-02-03T08:26:41Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 1860-7179 | |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202200583 | |
dc.identifier.uri | http://radar.ibiss.bg.ac.rs/handle/123456789/5432 | |
dc.description.abstract | Fenoprofen is a widely used nonsteroidal anti-inflammatory drug (NSAID) against rheumatoid arthritis, degenerative joint disease, ankylosing spondylitis and gout. Like other NSAIDs, fenoprofen inhibits the synthesis of prostaglandins by blocking both cyclooxygenase (COX) isoforms, COX-1 the “house-keeping” enzyme and COX-2 the induced isoform from pathological stimuli. Unselective inhibition of both COX isoforms results in many side effects, but off-target effects have also been reported. The steric modifications of the drugs could afford the desired COX-2 selectivity. Furthermore, NSAIDs have shown promising cytotoxic properties. The structural modification of fenoprofen using bulky dicarba-closo-dodecaborane(12) (carborane) clusters and the biological evaluation of the carborane analogues for COX inhibition and antitumor potential showed that the carborane analogues exhibit stronger antitumor potential compared to their respective aryl-based compounds. | |
dc.publisher | John Wiley and Sons Ltd | |
dc.relation | info:eu-repo/grantAgreement/MESTD/inst-2020/200007/RS// | |
dc.relation | Deutscher Akademischer Austauschdienst 57381412 | |
dc.relation | Deutsche Forschungsgemeinschaft He 1376/54‐1, PI‐304/7‐1 | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.source | ChemMedChem | |
dc.subject | cancer | |
dc.subject | Carborane | |
dc.subject | COX inhibitors | |
dc.subject | drug design | |
dc.subject | fenoprofen | |
dc.title | Carborane Analogues of Fenoprofen Exhibit Improved Antitumor Activity | |
dc.type | article | en |
dc.rights.license | BY-NC-ND | |
dc.rights.holder | © 2022 The Authors. ChemMedChem published by Wiley-VCH GmbH | |
dc.citation.issue | 5 | |
dc.citation.volume | 18 | |
dc.identifier.doi | 10.1002/cmdc.202200583 | |
dc.identifier.pmid | 36583943 | |
dc.identifier.scopus | 2-s2.0-85146469898 | |
dc.identifier.wos | 000914767400001 | |
dc.citation.apa | Useini, L., Mojić, M., Laube, M., Lönnecke, P., Mijatović, S., Maksimović‐Ivanić, D., et al. (2023). Carborane Analogues of Fenoprofen Exhibit Improved Antitumor Activity. ChemMedChem, 18(5) e202200583. | |
dc.citation.vancouver | Useini L, Mojić M, Laube M, Lönnecke P, Mijatović S, Maksimović‐Ivanić D, Pietzsch J, Hey‐Hawkins E. Carborane Analogues of Fenoprofen Exhibit Improved Antitumor Activity. ChemMedChem. 20232;18(5):e202200583. | |
dc.citation.spage | e202200583 | |
dc.type.version | publishedVersion | |
dc.identifier.fulltext | https://radar.ibiss.bg.ac.rs/bitstream/id/12296/bitstream_12296.pdf | |
dc.citation.rank | M22 |